Price (90d)
$26.11Signal Score (90d)
164Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $644.86M | $196.05M | $1.05 |
| 2025 | $570.40M | $223.19M | $1.19 |
| 2024 | $475.42M | $147.58M | $0.78 |
| 2023 | $419.05M | $112.82M | $0.58 |
| 2022 | $343.55M | $154.78M | $0.81 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $0.36 per share
Typical surprise +18.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.29 vs $0.30miss
- Wed, May 13$0.26 vs $0.28miss
- Thu, Feb 5$0.46 vs $0.44beat
- Thu, Nov 6$0.45 vs $0.38beat
- Thu, Aug 7$0.36 vs $0.30beat
- Thu, May 15$0.38 vs $0.27beat
Estimates and results for DOCS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DOCS's reported EPS growth of 6.7% a year over 4 years.
- EPS in 5 years
- $1.45
- Implied price
- $31.90
- Return from $24.80
- 5.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $15.86 — -36.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| -3.3% | -10.6% | -7.4% | -4.7% | -2.2% | 0.0% |
| 1.7% | -6.0% | -2.7% | 0.2% | 2.8% | 5.2% |
| 6.7% | -1.3% | 2.1% | 5.2% | 7.9% | 10.4% |
| 11.7% | 3.3% | 6.9% | 10.1% | 12.9% | 15.5% |
| 16.7% | 7.9% | 11.7% | 15.0% | 18.0% | 20.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (5)
- News (Marketaux)finance.yahoo.com·6d ago·Positive
Why Doximity Stock Skyrocketed on Friday Shares of Doximity (NYSE</e[+253 characters]
View source ↗ - Newsfool.com·7d ago·Positive
Why Doximity Stock Skyrocketed on Friday Doximity's AI assistant is earning favorable reviews from independent researchers. Customer usage of Doximity's AI services is soaring.
View source ↗ - Newsseekingalpha.com·7d ago·Neutral
Doximity: I Called The Pop Over A Month Ago, But Now Is The Time To Wait (Rating Downgrade) Doximity delivered strong fiscal Q1 2027 results, validating my prior bullish stance on valuation and AI-driven growth. The stock surged over 30% intraday, reflecting the market's recognition of DOCS's evolving business model and earnings strength. DOCS is transforming physician searches into a new commercial marketplace, leveraging AI Search to monetize real-time physician intent.
View source ↗ - Newsmarketbeat.com·7d ago·Neutral
Doximity Q1 Earnings Call Highlights Doximity NYSE: DOCS reported fiscal 2027 first-quarter revenue of $157 million, up 7% from a year earlier, as the company cited improving demand from pharmaceutical and hospital customers and increased engagement with its clinical artificial intelligence tools.
View source ↗ - 4chan /biz/biz·8d ago·Neutral
DOCS up 80% AH
View source ↗